Sichenzia Ross Friedman Ference LLP Advises Can-Fite Biopharmaceuticals on Multi-Million Dollar Licensing Agreement with Cipher Pharmaceuticals
Sichenzia Ross Friedman Ference LLP Advises Can-Fite Biopharmaceuticals on Multi-Million Dollar Distribution Agreement with Cipher Pharmaceuticals
New York – April 1, 2015 – Securities and Corporate law firm Sichenzia Ross Friedman Ference LLP has announced today that the Firm represented Can-Fite Biopharmaceuticals Ltd., (NYSE MKT: CANF) an Israeli biopharmaceutical company developing therapeutic products, in a multi million dollar Distribution Agreement where Cipher Pharmaceuticals, Inc. will distribute Can-Fite’s leading drug candidate, CF101 in the Canadian market for certain indications upon receipt of regulatory approval.
The Sichenzia Ross Friedman Ference LLP team was led by Partner Greg Sichenzia and Gary Emmanuel.
Media Contact:
pr@srf.law
(212)-930-9700
- Sichenzia Ross Ference Carmel LLP (思成律师事务所/SRFC) 代表 Ribbon Acquisition Corp 完成在纳斯达克交易所5000万美元的首次公开发行 (IPO) - January 15, 2025
- Sichenzia Ross Ference Carmel LLP Represents Craft Capital Management in $600,000 Public Offering of Giftify, Inc. - January 15, 2025
- Sichenzia Ross Ference Carmel LLP Represents Aegis Capital Corp. in $15 Million Public Offering of Li-Cycle - January 15, 2025